Co-Diagnostics Q2 2026 Earnings: Losses Narrow as Revenue Stays Near $0.17 Million

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 revenue of $166,131, up about 2% from $162,910 a year earlier, while GAAP loss per basic and diluted share improved to $1.46 from $7.00. Lower operating expenses narrowed the net loss to $6.28 million, but gross profit declined and cash fell to $3.65 million as the company continued funding regulatory and commercialization work.

Core financial results

Revenue changed little because higher product sales added only about $3,000 year over year. Gross profit fell despite that increase, as cost of revenue rose to $45,303 from $32,106 and reduced gross margin by approximately 7.6 percentage points.

Expense reductions were the main reason losses narrowed. General and administrative expenses declined to $1.50 million from $2.60 million, while research and development spending fell to $4.15 million from $4.69 million. The company attributed the reductions partly to lower legal, personnel, and stock-based compensation costs.

Adjusted EBITDA is a non-GAAP measure that excludes items including depreciation and amortization, stock-based compensation, interest, taxes, and changes in contingent consideration.

Commercial and product progress

All reported quarterly revenue came from product sales. Within its existing commercial operations, Co-Diagnostics expanded the Vector Smart customer footprint to 21 U.S. states and completed four new mosquito-abatement laboratory installations during the quarter.

The more consequential developments concerned the Co-Dx PCR platform, which has not yet been cleared or authorized by the FDA and is not currently available for sale. Co-Diagnostics completed clinical and analytical work supporting its FDA submission for the Flu A/B & RSV test, including a clinical study involving more than 1,400 patients at nine U.S. sites and an analytical program covering 27 studies and more than 10,000 PCR test runs. It subsequently submitted a 510(k) notification and concurrent CLIA Waiver by Application.

International initiatives included starting clinical performance studies in India for the CoSara PCR MTB test, securing approval for a planned manufacturing site and signing a lease in Saudi Arabia, and entering a distribution agreement covering Mexico. These actions expand the company’s potential regulatory, manufacturing, and distribution infrastructure, but no related revenue contribution was disclosed.

Expense reductions narrowed losses while liquidity tightened

The quarter’s improved losses came primarily from lower spending rather than revenue expansion. Operating expenses of $6.32 million remained far above quarterly revenue of $0.17 million, while the lower gross margin shows that the modest sales increase did not create operating leverage at the gross-profit level.

Cash and cash equivalents declined to $3.65 million on June 30, 2026, from $11.88 million at the end of 2025, a reduction of approximately $8.2 million over six months. Co-Diagnostics also completed a $3.0 million private placement during the quarter, providing additional capital while it continued investing in clinical studies, manufacturing, and commercialization.

The improvement in per-share loss should also be viewed alongside the higher share count. Weighted-average shares increased to 4.31 million from 1.10 million a year earlier, while shares outstanding reached 4.88 million at quarter-end versus 2.10 million at the end of 2025. The larger denominator therefore contributed to the per-share improvement, which was much greater than the approximately 19% narrowing of the net loss.

Risks investors need to watch

• Regulatory timing and outcomes: The Co-Dx PCR platform and its associated tests remain subject to FDA and other regulatory reviews. Delays or unfavorable outcomes would postpone commercialization and the potential revenue needed to support the company’s cost base.
• Liquidity and financing: Cash declined substantially during the first half despite the $3.0 million private placement. Continued losses may require additional capital, potentially increasing dilution or constraining development plans.
• Commercial adoption: Regulatory submission is an important milestone, but the company still must translate clearance, if obtained, into manufacturing scale, distribution, customer adoption, and material revenue.
• International execution: Programs in India, Saudi Arabia, Mexico, and other markets depend on local approvals, joint ventures, distributors, manufacturers, and other third parties, creating execution and timing risks.

Summary

Co-Diagnostics reduced its Q2 2026 operating and net losses mainly through lower administrative and research spending, while revenue remained near $0.17 million and gross margin declined. Regulatory submissions, international manufacturing plans, and new distribution arrangements moved the Co-Dx PCR platform closer to potential commercialization, but the platform remains unavailable for sale. The main issues ahead are regulatory progress, the conversion of development milestones into meaningful revenue, and the company’s ability to fund operations while cash balances decline.